Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine

Thrombosis Research

Volumn 111, Issue 4-5, 2003, Pages 273-279

  Mouton, Christine ^a   Calderon, Joachim ^a   Janvier, Gérard ^a   Vergnes, Marie Christine ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Anti Xa activity; Cardiopulmonary bypass; Dextran sulfate; Protamine sulfate

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; COAMATIC; DEXTRAN SULFATE; HEPARIN; HEPARIN ANTAGONIST; PROTAMINE; REAGENT; ROTACHROM; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEART SURGERY; HUMAN; IN VITRO STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; THROMBIN TIME; THROMBOSIS PREVENTION;

EID: 0345802672     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.09.014     Document Type: Article

References (20)

1. Despotis G.J., Gravlee G., Filos K., Levy J. Anticoagulation monitoring during cardiac surgery. A review of current and emerging techniques. Anesthesiology. 91:1999;1122-1151.
2. Cannon C.P. The pharmacology of anticoagulation. Roque Pifarré In anticoagulation, hemostasis, and blood preservation in cardiovascular surgery. 1993;Hanley & Belfus, Philadelphia.
3. Harenberg J., Siegele M., Dempfle C.E., Stehle G., Heene D.L. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb. Haemost. 70:1993;942-945.
4. Bevan D.H. Cardiac bypass haemostasis: putting blood through the mill. Br. J. Haematol. 104:1999;208-219.
5. Racanelli A., Fareed J., Walenga J.M., Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Semin. Thromb. Hemost. 11:1995;176-189.
6. Racanelli A., Fareed J. Neutralization of the antithrombotic effects of heparin and fraxiparin® by protamine sulfate. Thromb. Res. 68:1992;211-222.
7. Hubbard A.R., Jennings A. Neutralisation of heparan sulphate and low molecular weight heparin by protamine. Thromb. Haemost. 53:1985;86-89.
8. Young E., Cosmi B., Weitz J., Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb. Haemost. 70:1993;625-630.
9. Crowther M., Berry L.R., Monagle P.T., Chan A.K.C. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br. J. Haematol. 116:2002;178-186.
10. Woodman R.C., Harker L.A. Bleeding complications associated with cardiopulmonary bypass. Blood. 76:1990;1680-1697.
11. Horrow J.C. Protamine: a review of its toxicity. Anesth. Analg. 64:1985;348-360.
12. Carr J.A., Silverman N. The heparin-protamine interaction. J. Cardiovasc. Surg. 40:1999;659-666.
13. Lyon S.G., Lasser E.C., Stein R. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct the effect of antithrombin III concentration. Thromb. Haemost. 58:1987;884-887.
14. Denton J., Lane D.A., Thunberg L., Slater A.M., Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem. J. 209:1983;455-460.
15. Horne M.K. The effect of secreted heparin-binding proteins on heparin binding to platelets. Thromb. Res. 70:1993;91-98.
16. Shanberge J.N., Quattrociocchi-Longe T.M., Martens M.H. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. Thromb. Res. 46:1987;89-100.
17. Lane D.A., Denton J., Flynn A.M., Thunberg L., Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem. J. 218:1984;725-732.
18. Wagner W.R., Johnson P.C., Thompson K.A., Marrone G.C. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann. Thorac. Surg. 58:1994;734-741.
19. Zeerleder S., Mauron T., Lämmle B., Wuillemin W.A. Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb. Res. 105:2002;441-446.
20. Young E., Wells P., Holloway S., Weitz J., Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb. Haemost. 71:1994;300-304.